DE60228971D1 - Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff - Google Patents

Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff

Info

Publication number
DE60228971D1
DE60228971D1 DE60228971T DE60228971T DE60228971D1 DE 60228971 D1 DE60228971 D1 DE 60228971D1 DE 60228971 T DE60228971 T DE 60228971T DE 60228971 T DE60228971 T DE 60228971T DE 60228971 D1 DE60228971 D1 DE 60228971D1
Authority
DE
Germany
Prior art keywords
synzytialvirus
vaccine
respiratory
peptides
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60228971T
Other languages
English (en)
Inventor
Nathalie Corvaia
Ngoc Thien Nguyen
Alain Beck
Gilquin Helene Plotnicky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Application granted granted Critical
Publication of DE60228971D1 publication Critical patent/DE60228971D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60228971T 2001-07-20 2002-07-19 Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff Expired - Fee Related DE60228971D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0109731A FR2827605B1 (fr) 2001-07-20 2001-07-20 Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
PCT/FR2002/002599 WO2003010317A1 (fr) 2001-07-20 2002-07-19 Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin

Publications (1)

Publication Number Publication Date
DE60228971D1 true DE60228971D1 (de) 2008-10-30

Family

ID=8865750

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228971T Expired - Fee Related DE60228971D1 (de) 2001-07-20 2002-07-19 Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff

Country Status (16)

Country Link
US (3) US7309494B2 (de)
EP (1) EP1409692B1 (de)
JP (1) JP4310184B2 (de)
CN (1) CN1556857A (de)
AT (1) ATE408696T1 (de)
AU (1) AU2002336148B8 (de)
BR (1) BR0211296A (de)
CA (1) CA2455360A1 (de)
DE (1) DE60228971D1 (de)
DK (1) DK1409692T3 (de)
ES (1) ES2314102T3 (de)
FR (1) FR2827605B1 (de)
MX (1) MXPA04000597A (de)
PT (1) PT1409692E (de)
WO (1) WO2003010317A1 (de)
ZA (1) ZA200400916B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60136381D1 (de) 2000-10-18 2008-12-11 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
EP1768993A4 (de) * 2004-06-16 2008-07-23 Univ Johns Hopkins Cysteinreiche region des humanen respiratorischen synzytial-virus und verwendungsverfahren dafür
EP1972348A1 (de) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Neue Impfstoffzusammensetzung zur Behandlung infektiöser Atemwegskrankheiten
EP2331127A2 (de) 2008-09-18 2011-06-15 Novartis AG Vakzine-adjuvans-kombinationen
CA2770304C (en) 2009-08-04 2019-11-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
JP2013503148A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
EP3047855A1 (de) 2009-12-21 2016-07-27 Cornell University Neuartige pneumoviruszusammensetzungen und verfahren zur verwendung davon
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
KR20140027211A (ko) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 백신 면역원성의 개선 방법
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
RU2014140336A (ru) 2012-03-07 2016-04-27 Новартис Аг Иммунологически полезные соли аргинина
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
KR20220119527A (ko) 2012-08-01 2022-08-29 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
CN105085684B (zh) * 2014-05-14 2020-04-17 上海亨臻实业有限公司 Pcsk9靶向重组疫苗设计及其应用
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
JP2019508419A (ja) 2016-02-16 2019-03-28 ザ ユニバーシティー オブ クイーンズランド 新規アルファコノトキシンペプチド
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
AU2020227545B2 (en) 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
US11360877B2 (en) * 2020-09-14 2022-06-14 International Business Machines Corporation Forming microservices from monolithic applications
WO2024084785A1 (ja) * 2022-10-20 2024-04-25 一般財団法人阪大微生物病研究会 Ｒｓウイルスワクチンとしての利用に好適な組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU605476B2 (en) 1986-01-14 1991-01-17 University Of North Carolina, The Vaccines for human respiratory virus
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
FR2766192B1 (fr) 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR2776521B1 (fr) 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Also Published As

Publication number Publication date
JP2005511010A (ja) 2005-04-28
US20090181042A1 (en) 2009-07-16
BR0211296A (pt) 2004-09-14
US7524627B2 (en) 2009-04-28
AU2002336148B8 (en) 2008-06-19
WO2003010317A1 (fr) 2003-02-06
EP1409692A1 (de) 2004-04-21
CA2455360A1 (fr) 2003-02-06
AU2002336148B2 (en) 2007-12-13
US20090036367A1 (en) 2009-02-05
US7309494B2 (en) 2007-12-18
CN1556857A (zh) 2004-12-22
MXPA04000597A (es) 2004-04-20
ES2314102T3 (es) 2009-03-16
JP4310184B2 (ja) 2009-08-05
FR2827605B1 (fr) 2004-07-16
EP1409692B1 (de) 2008-09-17
PT1409692E (pt) 2008-12-26
US20040175395A1 (en) 2004-09-09
DK1409692T3 (da) 2009-02-02
ATE408696T1 (de) 2008-10-15
ZA200400916B (en) 2004-08-25
FR2827605A1 (fr) 2003-01-24

Similar Documents

Publication Publication Date Title
DE60228971D1 (de) Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
EP1594536A4 (de) Adjuvante influenza-vakzine
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MXPA05009580A (es) Vacuna contra el virus de la influenza.
EA201070794A1 (ru) Рекомбинантные антигены rsv
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
ATE542829T1 (de) Impfstoff
HK1125051A1 (en) Virus-like particles as vaccines for paramyxovirus
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
WO2006115843A3 (en) Nipah virus vaccines
CY1109036T1 (el) Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
WO2002058725A3 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
PE20060860A1 (es) Vacuna basada en epitopes neutralizantes
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
ATE411812T1 (de) Peptide zur behandlung von infektionen mit dem herpes-virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee